About Syed Kazmi

President & Chief executive officer, and member of Board of Directors at a precision therapeutics biotech, Jubilant Therapeutics. An accomplished career of over 30 years in executive and operational leadership, BD&L and R&D in both specialty biotech and large pharma companies. Built and grew an innovative biotech from bench to bedside on an accelerated growth trajectory with two INDs approved and the lead program in FIH clinical trials Specialize in scientific/business evaluations, acquisitions, divestitures, and global licensing/partnering of high value pipeline, emerging technologies and commercial assets. Led acquisition and integration of multiple public and private biotech companies and late-stage assets using structured transactions to expand global market share, revenue streams, and geographic footprints. Extensive international business experience with multiple transactions in EU and emerging markets. Led cross-functional product development teams for large Phase III pivotal studies, FDA/EMEA approvals and launch of multiple oncology drugs.

Specialties:
• Build and grow innovative Biotech startup in oncology and autoimmune disorders; hiring and
mentoring high performance teams including C-suite; advance novel pre-clinical programs to IND
filing and first in human PoC studies
• Unique combination of scientific and business expertise to lead oncology drug development
programs
• Buy & Sell side transactions
• Transactions across pre-POC to Commercial assets
• Business case analysis for CEO and executive leadership
• Therapeutic area strategy and portfolio prioritization
• Deep understanding of emerging industry landscape and competitive dynamics
• M&A and post-deal integration
• International cross-cultural business deals
• Extensive network of senior biotech and pharma executives